- Details
- Phillip Koo and Daniel Saltzstein delve into the ECLIPSE clinical trial. The trial, aiming to enroll over 400 patients, brings Lutetium-177, a radioligand therapy, to patients with metastatic castrate-resistant prostate cancer at an earlier stage than it's currently approved for. Dr. Saltzstein outlines the trial's inclusion criteria, notably patients with castrated testosterone, PSA progression,...
|
- Details
- Alicia Morgans engages with Scott Tagawa regarding his team's presentations on a phase one study highlighting the combination of an alpha and beta emitter targeting PSMA in prostate cancer. Despite being a preliminary trial, the research reveals promising safety profiles for the combined approaches, along with potential early efficacy signals, such as PSA reductions and circulating tumor cell conv...
|
- Details
- In this conversation, Sam Chang discusses a publication with Mark Tyson that focuses on the use of the TAR-200 device in patients with muscle-invasive bladder cancer. The study aimed to understand the safety, tolerability, and preliminary efficacy of the device in patients who were not suitable for radical cystectomy or radiation therapy. The initial findings showed that the device was well-tolera...
|
- Details
- Emmanuel Antonarakis joins Alicia Morgans in a conversation about the trial in progress multicenter, open-label, randomized phase 3 ECLIPSE trial comparing the safety and efficacy of 177Lu-PSMA-I&T versus standard-of-care hormone therapy in patients with metastatic castration-resistant prostate cancer, previously treated with only one ARAT and are taxane-based chemo naive. The ECLIPSE trial is bei...
|
- Details
- Jones Nauseef speaks with Alicia Morgans about a trial in progress dose-escalation study of fractionated 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC) in patients with prior treatment with 177Lu-PSMA. With the approval of Lutetium 177 Jones Nauseef explains that the study team decided to modify the study design to include a post-177-Lu-PSMA cohort because patie...
|
- Details
- This phase II trial, Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer (IMMORTAL) investigates the impact of adding radiation therapy to immunotherapy compared to immunotherapy alone for metastatic urothelial cancer. Radiation therapy, specifically stereotactic body radiation therapy (SBRT), may shrink tumors but can have side effects. Immunotherapy with monoclonal a...
|
- Details
- Alicia Morgans and Carsten-Henning Ohlmann discuss the SPARE trial, an exploratory phase two study involving chemo-naive metastatic castration-resistant prostate cancer patients. The trial compares the standard of care - ADT (Androgen Deprivation Therapy) plus abiraterone plus prednisone, versus abiraterone plus prednisone without the continuation of ADT. Preliminary results show no significant di...
|
- Details
- Tiago Padua presents an overview of ongoing clinical trials in rare GU tumors, including adrenal tumors, testicular cancer, and penile cancer, at a medical conference. He emphasizes the challenges of treating these tumors due to lack of guidelines, low recruitment, limited funds, and underscores the importance of international collaboration. Details are provided about several trials, such as a Pha...
|
- Details
- Noel Clarke delivers a comprehensive discussion about the STAMPEDE trial model, focusing on its innovative approach to prostate cancer treatment in the UK. He elaborates on the multi-arm, multi-stage (MAMS) trial design, emphasizing its flexibility and efficiency, and the collaboration with large data sets like the National Prostate Cancer Audit. Dr. Clarke highlights significant results, such as...
|
- Details
- Pedro Barata hosts Nizar Tannir to discuss the CANTATA trial for advanced renal cell carcinoma (RCC) treatment. Dr. Tannir explicates the historical progression of RCC therapies, emphasizing the biological implications of glucose metabolism in tumor cells and the need for alternative energy sources such as glutamine. Telaglenastat, a glutaminase inhibitor, offers a potential breakthrough, disrupti...
|
